Bondbloxx Bloomberg Ten Year Target Duration US Treasury ETF XTEN
Set alert
At close · Oct 30
After hours · Oct 30, 5:05 PM ET
- YTD
- -5.00%
- 1 year
- -6.44%
- Open
- 43.91
- Prev close
- 43.71
- Mkt cap
- 1.04B
- Vol
- 270.17K
- Avg vol
- 325.33K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 43.77
- High
- 43.98
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 43.37
- 200-d avg
- 45.04
- 1y target
- 0.00
News
1 week ago defenseworld.net
BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTEN Stake Reduced by DUTCH ASSET Corp
DUTCH ASSET Corp cut its stake in BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF (NYSEARCA:XTEN) by 20.6% during the undefined quarter, according to its most recent Form 13F filing with…
2 weeks ago defenseworld.net
BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF (NYSEARCA:XTEN) Stock Short Interest Report for September
BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF (NYSEARCA:XTEN - Get Free Report) saw a large increase in short interest in the month of September. As of September 30th, there was short…
2 weeks ago defenseworld.net
15,395 Shares in BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTEN Bought by Sax Wealth Advisors LLC
Sax Wealth Advisors LLC bought a new position in BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF (NYSEARCA:XTEN) during the undefined quarter, according to its most recent filing with…
2 weeks ago businesswire.com
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN® dual-masked…
3 weeks ago businesswire.com
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted…
3 months ago etftrends.com
Why Investors Are Eyeing Short & Long U.S. Treasury ETFs
Considering where bond yields sit, along with geopolitical pressures and potential policy from the Fed, there are plenty of ways for advisors and investors to play the fixed income market at the…
6 months ago businesswire.com
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500,…
7 months ago defenseworld.net
Park Avenue Securities LLC Sells 37,510 Shares of BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTEN
Park Avenue Securities LLC lowered its position in shares of BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF (NYSEARCA:XTEN) by 19.8% during the undefined quarter, according to its most…
8 months ago businesswire.com
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen…
9 months ago defenseworld.net
Heck Capital Advisors LLC Has $9.10 Million Stock Holdings in BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTEN
Heck Capital Advisors LLC lifted its stake in shares of BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF (NYSEARCA:XTEN) by 9.5% in the third quarter, according to its most recent Form…
1 year ago businesswire.com
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in Part 3 of the Company's Phase 1 clinical trial evaluating VIR-5500 in…
1 year ago businesswire.com
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Company's Phase 1 clinical trial evaluating VIR-5525, an…
1 year ago etftrends.com
BondBloxx Fixed Income ETFs Surpass $4 Billion in Total AUM
Fixed income firm BondBloxx celebrated a new milestone recently, crossing $4 billion in ETF AUM. The firm offers more than 20 fixed income ETFs for investors, led by its largest fund, the BondBloxx…
1 year ago etftrends.com
Market Valuation, Inflation and Treasury Yields – January 2025
Our monthly market valuation updates have long had the same conclusion: US stock indexes are significantly overvalued, which suggests cautious expectations for investment returns. On August 4, 2020,…
1 year ago etftrends.com
Market Valuation, Inflation and Treasury Yields – December 2024
Our monthly market valuation updates have long had the same conclusion: US stock indexes are significantly overvalued, which suggests cautious expectations for investment returns. On August 4, 2020,…
1 year ago etftrends.com
Market Valuation, Inflation and Treasury Yields – November 2024
Our monthly market valuation updates have long had the same conclusion: US stock indexes are significantly overvalued, which suggests cautious expectations for investment returns. On August 4, 2020,…
1 year ago businesswire.com
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell engagers…
1 year ago etftrends.com
Market Valuation, Inflation and Treasury Yields – October 2024
Our monthly market valuation updates have long had the same conclusion: US stock indexes are significantly overvalued, which suggests cautious expectations for investment returns. On August 4, 2020,…
2 years ago etftrends.com
Market Valuation, Inflation and Treasury Yields – September 2024
Our monthly market valuation updates have long had the same conclusion: US stock indexes are significantly overvalued, which suggests cautious expectations for investment returns. On August 4, 2020,…
2 years ago etftrends.com
Market Valuation, Inflation and Treasury Yields – August 2024
Our monthly market valuation updates have long had the same conclusion: US stock indexes are significantly overvalued, which suggests cautious expectations for investment returns. On August 4, 2020,…
-
3 years ago benzinga.com
5 ETFs To Watch As 10-Year Treasury Approaches 5% Yield, Analysts Say It's Now A 'Buy'
The 10-year Treasury bond is closely monitored by several exchange-traded funds (ETFs), including iShares 7-10 Year Treasury Bond ETF.
-
3 years ago benzinga.com
Economists See Recession Risk Waning, End Of Fed Rate Hikes: How Could Treasury ETFs React To Yields?
Economists anticipate the 10-year Treasury yield to conclude this year at 4.47%, with a further drop to 4.16% by the end of June next year.